Core Viewpoint - Yingliu Co., Ltd. has shown significant trading activity and financial performance, indicating potential investment interest and market positioning. Group 1: Trading Activity - On January 9, Yingliu shares rose by 1.96% with a trading volume of 1.134 billion yuan [1] - The margin trading data shows that on the same day, the financing purchase amount was 141 million yuan, while the financing repayment was 93.5869 million yuan, resulting in a net financing purchase of 47.8139 million yuan [1] - As of January 9, the total margin trading balance for Yingliu was 507 million yuan, with the financing balance accounting for 1.66% of the circulating market value, indicating a high level compared to the past year [1] Group 2: Shareholder and Financial Performance - As of September 30, the number of shareholders for Yingliu increased by 13.54% to 25,600, while the average circulating shares per person decreased by 11.93% to 26,505 shares [2] - For the period from January to September 2025, Yingliu achieved an operating income of 2.121 billion yuan, representing a year-on-year growth of 11.02%, and a net profit attributable to shareholders of 294 million yuan, up 29.59% year-on-year [2] - Since its A-share listing, Yingliu has distributed a total of 558 million yuan in dividends, with 250 million yuan distributed over the past three years [2] Group 3: Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the second-largest circulating shareholder of Yingliu, holding 38.5922 million shares, an increase of 6.5246 million shares from the previous period [2] - The third-largest circulating shareholder, Quan Guo Xu Yuan Three-Year Holding Period Mixed A, held 32.5932 million shares, which is a decrease of 196,700 shares compared to the previous period [2]

Core Viewpoint - Hongqi Chain's stock price increased by 3.00% on January 9, with a trading volume of 817 million yuan, indicating positive market sentiment despite a net financing outflow [1] Financing Summary - On January 9, Hongqi Chain had a financing buy-in amount of 85.77 million yuan and a financing repayment of 112 million yuan, resulting in a net financing outflow of 26.01 million yuan [1] - As of January 9, the total financing and securities lending balance for Hongqi Chain was 423 million yuan, with the financing balance accounting for 5.01% of the circulating market value, indicating a high level compared to the past year [1] - The company had a securities lending repayment of 4,500 shares and a securities lending sell-out of 7,700 shares on January 9, with a sell-out amount of 47,700 yuan [1] Business Performance Summary - As of December 10, the number of shareholders for Hongqi Chain was 68,600, an increase of 5.19%, while the average circulating shares per person decreased by 4.93% [2] - For the period from January to September 2025, Hongqi Chain reported an operating income of 7.11 billion yuan, a year-on-year decrease of 8.48%, and a net profit attributable to shareholders of 383 million yuan, a year-on-year decrease of 1.89% [2] - Since its A-share listing, Hongqi Chain has distributed a total of 1.56 billion yuan in dividends, with 926 million yuan distributed over the past three years [2] Shareholding Structure Summary - As of September 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder of Hongqi Chain, holding 35.23 million shares, a decrease of 19.98 million shares compared to the previous period [2] - The Southern CSI 1000 ETF ranked as the tenth largest circulating shareholder, holding 6.23 million shares, a decrease of 250,500 shares compared to the previous period [2]

分红方面，我武生物A股上市后累计派现9.13亿元。近三年，累计派现3.17亿元。 1月9日，我武生物涨2.43%，成交额2.19亿元。两融数据显示，当日我武生物获融资买入额2206.14万 元，融资偿还2095.29万元，融资净买入110.85万元。截至1月9日，我武生物融资融券余额合计4.31亿 元。 机构持仓方面，截止2025年9月30日，我武生物十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股556.20万股，相比上期增加145.24万股。嘉实互融精选股票A（006603）位居第六大流通 股东，持股471.18万股，为新进股东。鹏华医药科技股票A（001230）位居第八大流通股东，持股 429.86万股，为新进股东。招商国证生物医药指数A（161726）位居第十大流通股东，持股390.68万 股，相比上期减少78.33万股。 责任编辑：小浪快报 资料显示，浙江我武生物科技股份有限公司位于浙江省德清县武康镇志远北路636号，成立日期2002年9 月19日，上市日期2014年1月21日，公司主营业务涉及从事过敏性疾病诊断及治疗产品的研发、生产和 销售。主营业务收入构成为：粉尘螨滴剂94.17% ...

1月9日，一心堂涨0.61%，成交额1.45亿元。两融数据显示，当日一心堂获融资买入额1644.09万元，融 资偿还1423.99万元，融资净买入220.10万元。截至1月9日，一心堂融资融券余额合计2.66亿元。 融资方面，一心堂当日融资买入1644.09万元。当前融资余额2.64亿元，占流通市值的3.40%，融资余额 超过近一年80%分位水平，处于高位。 分红方面，一心堂A股上市后累计派现20.23亿元。近三年，累计派现7.64亿元。 机构持仓方面，截止2025年9月30日，一心堂十大流通股东中，香港中央结算有限公司位居第三大流通 股东，持股2231.44万股，相比上期增加374.00万股。融通健康产业灵活配置混合A/B（000727）位居第 五大流通股东，持股1650.00万股，相比上期增加322.00万股。兴全趋势投资混合(LOF)（163402）位居 第六大流通股东，持股600.00万股，为新进股东。兴全合泰混合A（007802）位居第七大流通股东，持 股486.31万股，为新进股东。兴全合衡三年持有混合A（014639）位居第八大流通股东，持股379.57万 股，为新进股东。融通鑫新成长混合A（0 ...

截至9月30日，晶方科技股东户数14.77万，较上期增加7.82%；人均流通股4416股，较上期减少7.26%。 2025年1月-9月，晶方科技实现营业收入10.66亿元，同比增长28.48%；归母净利润2.74亿元，同比增长 48.40%。 分红方面，晶方科技A股上市后累计派现4.96亿元。近三年，累计派现1.30亿元。 机构持仓方面，截止2025年9月30日，晶方科技十大流通股东中，东吴移动互联混合A（001323）位居 第二大流通股东，持股960.00万股，相比上期减少485.75万股。香港中央结算有限公司位居第三大流通 股东，持股897.88万股，相比上期增加489.32万股。南方中证1000ETF（512100）位居第四大流通股 东，持股596.50万股，相比上期减少5.71万股。国联安半导体ETF（512480）位居第六大流通股东，持 股445.56万股，为新进股东。华夏中证1000ETF（159845）位居第七大流通股东，持股354.50万股，相 比上期减少6000.00股。广发中证1000ETF（560010）位居第十大流通股东，持股274.04万股，为新进股 东。国联安中证全指半导体产品与设 ...

Core Viewpoint - On January 9, Hebang Biotechnology's stock price remained unchanged, with a trading volume of 355 million yuan, indicating a stable market position despite fluctuations in financing activities [1]. Financing Summary - On January 9, Hebang Biotechnology had a financing buy-in amount of 54.7361 million yuan and a financing repayment of 62.7429 million yuan, resulting in a net financing outflow of 8.0068 million yuan [1]. - The total financing and securities balance for Hebang Biotechnology reached 576 million yuan, with the financing balance of 568 million yuan accounting for 2.76% of the circulating market value, which is above the 50th percentile level over the past year [1]. - In terms of securities lending, 30,100 shares were repaid, while 35,900 shares were sold, with a selling amount of 83,600 yuan calculated at the closing price [1]. Company Overview - Hebang Biotechnology, established on August 1, 2002, and listed on July 31, 2012, is located in Leshan, Sichuan Province. The company specializes in the manufacturing of pesticides and pesticide intermediates, fine chemical products, intelligent glass, special glass, and the development of soda ash and ammonium chloride [1]. - The revenue composition of Hebang Biotechnology includes 85.89% from chemical products, 17.61% from photovoltaic glass and other products, 6.74% from mineral products, and 5.02% from other businesses [1]. Financial Performance - As of September 30, the number of shareholders for Hebang Biotechnology was 196,500, a decrease of 1.99% from the previous period, while the average circulating shares per person increased by 2.03% to 44,939 shares [2]. - For the period from January to September 2025, Hebang Biotechnology reported a revenue of 5.927 billion yuan, a year-on-year decrease of 13.02%, and a net profit attributable to shareholders of 93.1085 million yuan, down 57.93% year-on-year [2]. Dividend Information - Since its A-share listing, Hebang Biotechnology has distributed a total of 1.205 billion yuan in dividends, with 553 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, the fourth largest circulating shareholder of Hebang Biotechnology is the Penghua CSI Sub-Segment Chemical Industry Theme ETF Link A, holding 92.7878 million shares as a new shareholder [3]. - The fifth largest shareholder, the Southern CSI 500 ETF, holds 90.0899 million shares, a decrease of 2.1844 million shares from the previous period [3]. - The Hong Kong Central Clearing Limited is the sixth largest shareholder, holding 89.2826 million shares, an increase of 16.0908 million shares from the previous period [3].

Group 1 - The core viewpoint of the news is that Longxin General has shown fluctuations in its stock performance and financing activities, with a notable increase in revenue and net profit year-on-year [1][2][3] Group 2 - On January 9, Longxin General's stock price fell by 0.85%, with a trading volume of 416 million yuan. The financing buy-in amount was 21.29 million yuan, while the financing repayment was 24.38 million yuan, resulting in a net financing outflow of 3.09 million yuan [1] - As of January 9, the total balance of margin trading for Longxin General was 240 million yuan, with a financing balance of 238 million yuan, accounting for 0.76% of the circulating market value, which is below the 10th percentile level over the past year [1] - In terms of securities lending, on January 9, Longxin General repaid 900 shares and sold 9,400 shares, with a selling amount of 142,200 yuan. The remaining securities lending volume was 168,300 shares, with a balance of 2.55 million yuan, exceeding the 60th percentile level over the past year [1] Group 3 - As of September 30, Longxin General had 35,400 shareholders, an increase of 18.78% from the previous period, while the average circulating shares per person decreased by 15.81% to 58,032 shares [2] - For the period from January to September 2025, Longxin General achieved operating revenue of 14.557 billion yuan, a year-on-year increase of 19.14%, and a net profit attributable to shareholders of 1.577 billion yuan, a year-on-year increase of 75.45% [2] Group 4 - Longxin General has distributed a total of 3.605 billion yuan in dividends since its A-share listing, with 1.191 billion yuan distributed in the last three years [3] - As of September 30, 2025, Hong Kong Central Clearing Limited was the third-largest circulating shareholder of Longxin General, holding 141 million shares, an increase of 34.85 million shares from the previous period [3]

Group 1 - On January 9, Luoyang Molybdenum Co., Ltd. saw a stock price increase of 5.07% with a trading volume of 5.808 billion yuan. The financing buy amount was 488 million yuan, while the financing repayment was 490 million yuan, resulting in a net financing outflow of 1.2631 million yuan. The total financing and securities lending balance reached 3.702 billion yuan as of January 9 [1] - The financing balance of Luoyang Molybdenum on January 9 was 3.674 billion yuan, accounting for 0.92% of the circulating market value, which is above the 90th percentile level over the past year, indicating a high level of financing [1] - In terms of securities lending, on January 9, Luoyang Molybdenum repaid 9,400 shares and sold 96,600 shares, with a selling amount of 2.2005 million yuan based on the closing price. The remaining securities lending volume was 1.2203 million shares, with a balance of 27.7984 million yuan, also exceeding the 90th percentile level over the past year [1] Group 2 - Luoyang Molybdenum Co., Ltd. was established on December 22, 1999, and listed on October 9, 2012. The company primarily engages in the mining, selection, deep processing, trading, and research of rare metals such as molybdenum, tungsten, and gold [2] - The main business revenue composition includes: refined metal product trading (48.56%), concentrate product trading (38.31%), copper (27.14%), cobalt (6.04%), molybdenum (3.12%), phosphorus (2.23%), niobium (1.88%), tungsten (1.17%), and others (0.11%) [2] - As of September 30, 2025, Luoyang Molybdenum achieved an operating income of 145.485 billion yuan, a year-on-year decrease of 5.99%, while the net profit attributable to shareholders increased by 72.61% to 14.280 billion yuan [2] Group 3 - Luoyang Molybdenum has distributed a total of 21.562 billion yuan in dividends since its A-share listing, with cumulative distributions of 10.576 billion yuan over the past three years [3] - As of September 30, 2025, among the top ten circulating shareholders of Luoyang Molybdenum, Hong Kong Central Clearing Limited held 669.5 million shares, an increase of 47.472 million shares compared to the previous period. Meanwhile, Huaxia SSE 50 ETF and Huatai-PB CSI 300 ETF saw reductions in their holdings [3]

Core Insights - Silver Bond Co., Ltd. experienced a stock decline of 1.48% on January 9, with a trading volume of 2.992 billion yuan [1] - The company reported a financing buy-in of 411 million yuan and a financing repayment of 402 million yuan on the same day, resulting in a net financing buy of 9.1261 million yuan [1] - As of January 9, the total financing and securities lending balance for Silver Bond was 1.032 billion yuan, with a financing balance of 1.030 billion yuan, accounting for 6.73% of the circulating market value, indicating a high level compared to the past year [1] Financing and Securities Lending - On January 9, the company had a securities lending repayment of 700 shares and a securities lending sale of 1,600 shares, with a sale amount of 29,800 yuan based on the closing price [1] - The remaining securities lending volume was 96,200 shares, with a securities lending balance of 1.7912 million yuan, also at a high level compared to the past year [1] Company Overview - Silver Bond Co., Ltd. is located in Wuxi City, Jiangsu Province, and was established on August 25, 1998, with its listing date on July 18, 2012 [1] - The company's main business involves the research, production, and sales of aluminum alloy composite materials, aluminum-based multi-metal composite materials, and non-composite aluminum alloys [1] - The revenue composition of the main business includes 99.37% from metal composite materials, 0.36% from other sources, and 0.27% from equipment manufacturing [1] Shareholder Information - As of December 31, the number of shareholders for Silver Bond was 65,900, an increase of 9.27% from the previous period [2] - The average circulating shares per person decreased by 8.48% to 10,787 shares [2] - For the period from January to September 2025, the company achieved a revenue of 4.527 billion yuan, representing a year-on-year growth of 18.81%, while the net profit attributable to the parent company was 63.9449 million yuan, a decrease of 41.60% year-on-year [2] Dividend and Institutional Holdings - Since its A-share listing, Silver Bond has distributed a total of 108 million yuan in dividends, with cumulative distributions of 24.6576 million yuan over the past three years [2] - As of September 30, 2025, among the top ten circulating shareholders, the Southern CSI 1000 ETF held 4.5068 million shares, a decrease of 65,600 shares from the previous period [2] - The Huaxia CSI 1000 ETF held 2.6805 million shares, with a reduction of 3,500 shares compared to the previous period, while the GF CSI 1000 ETF has exited the top ten circulating shareholders list [2]

截至12月31日，博雅生物股东户数3.01万，较上期减少0.03%；人均流通股16737股，较上期增加 0.03%。2025年1月-9月，博雅生物实现营业收入14.74亿元，同比增长18.38%；归母净利润3.43亿元，同 比减少16.90%。 分红方面，博雅生物A股上市后累计派现10.07亿元。近三年，累计派现4.89亿元。 机构持仓方面，截止2025年9月30日，博雅生物十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股888.43万股，相比上期减少1815.54万股。招商国证生物医药指数A（161726）位居第六大 流通股东，持股434.18万股，相比上期减少75.06万股。 1月9日，博雅生物涨0.82%，成交额1.10亿元。两融数据显示，当日博雅生物获融资买入额1734.47万 元，融资偿还3523.80万元，融资净买入-1789.33万元。截至1月9日，博雅生物融资融券余额合计6.85亿 元。 融资方面，博雅生物当日融资买入1734.47万元。当前融资余额6.83亿元，占流通市值的5.76%，融资余 额超过近一年80%分位水平，处于高位。 融券方面，博雅生物1月9日融券偿还3300.0 ...